Care continues to improve; however, drug-resistant pathogens and a lack of new agents to treat these infections remain a constant challenge.
David Cluck, PharmD, BCPS, AAHIVP
Advertisement
Articles by David Cluck, PharmD, BCPS, AAHIVP
Should clinicians be extra vigilant when deciding who receives antiviral therapy, or are the adverse effects few and infrequent?
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Two Outbreaks Reveal a Dangerous Double Standard in Global Health
2
From Deadly Disease to Chronic Condition: How the Evolution of HIV Treatment Has Allowed People to Live Longer, Better Lives
3
FDA Accepts Shionogi's sNDA to Expand Cefiderocol Use to Pediatric Patients With Drug-Resistant Gram-Negative Infections
4
CDC, FDA Investigate Multistate Cyclospora Outbreak Linked to Taco Bell Shredded Lettuce
5